How often is Ranibizumab (Susvimo) delivered?

Ranibizumab, particularly in its formulation known as Susvimo, is delivered every 6 months for the treatment of certain retinal diseases, including age-related macular degeneration (AMD) and other causes of choroidal neovascularization (CNV). This extended dosing interval is a significant advancement in the management of these conditions, as it reduces the frequency of injections that patients need to experience compared to earlier formulations that required monthly administration.

Delivering Ranibizumab every 6 months allows for sustained efficacy in controlling the conditions it treats, thereby improving patient adherence and overall satisfaction with the treatment regimen. The extended-release formulation takes advantage of a novel delivery system that maintains therapeutic levels of the drug over a longer period, distinguishing it from other intravitreal therapies that necessitate more frequent dosing. This enhancement in treatment strategy reflects ongoing advancements in ocular therapies aimed at improving outcomes for patients with AMD.